Fosamax and Osteonecrosis of the Jaw: What Studies Show About Risk and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Assessment

The legacy domain of general health and science information has long served as a foundational resource for public understanding of medical risks and therapeutic benefits. Within this broad context, audiences have historically engaged with content that explains how pharmaceutical interventions interact with biological systems, often focusing on efficacy and safety profiles. This heritage provides a necessary baseline for interpreting clinical data and making informed health decisions. Transitioning from this general framework, a more focused inquiry emerges when considering specific drug-exposure scenarios and their potential downstream consequences. In the context of mass production and widespread pharmaceutical distribution, the question of occupational or environmental exposure to compounds such as bisphosphonates becomes salient. While the general health narrative addresses patient-level risk, the industrial and clinical handling of these substances introduces a distinct dimension of concern. Specifically, the relationship between Fosamax exposure and the risk of osteonecrosis of the jaw represents a pivot point where population-level health information must be refined to account for exposure intensity, duration, and context. This shift moves the discussion from broad therapeutic education toward a targeted assessment of risk factors associated with repeated or high-level contact, thereby bridging general awareness with occupational safety considerations.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation and diagnosis of ONJ involve identifying areas of exposed bone in the maxillofacial region that persist for more than eight weeks, often accompanied by pain, swelling, or infection. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanisms and Risk Factors for ONJ in Fosamax Users

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research suggests that bisphosphonates suppress bone turnover by inhibiting osteoclast activity, which can impair the jawbone's ability to remodel and heal after minor trauma, such as dental procedures. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and cellular properties of the jawbone that may make it particularly susceptible to the effects of bisphosphonates. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline of Exposure and Symptom Onset

Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Causation Evidence

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information, which includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may affect the perception of risk. Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax use and the development of ONJ, as well as the presence of other risk factors. A cohort study among cancer-free female patients aged 40-89 with, or at risk for, osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study provides evidence of a dose-response relationship, with longer exposure associated with higher risk, supporting a causal link.

Summary of Fosamax and ONJ Risk

In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of other risk factors such as invasive dental procedures. The prescribing information includes warnings about this risk, and patients should be counseled on maintaining good oral hygiene and avoiding invasive dental procedures while on bisphosphonate therapy. The absolute risk remains low, but the risk increases with cumulative exposure.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax (alendronate), a bisphosphonate, has been reported to increase the risk of ONJ, particularly with longer duration of use and in the presence of other risk factors such as invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk increases with longer duration of bisphosphonate exposure.

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of symptoms can vary from one day to several months after starting the drug. Most patients experience relief after stopping the medication, but some may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Is there evidence of a dose-response relationship between Fosamax and ONJ?

Yes, a cohort study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, supporting a dose-response relationship. Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.